The global epigenetics drugs and diagnostic technologies market size is expected to reach USD 22.05 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a 19.7% CAGR during the forecast period. Rising incidence of cancer with epigenetic modification base is projected to drive the market growth.
Diagnostic firms are focused on
developing new treatments such as antibodies specific for detection of
epigenetic modifications and advanced kits for effective detection of
biomarkers. It is likely to encourage pharmaceutical firms to partner for
development of new advanced treatments which will further accelerate the market
growth.
Presence of a large number of
products under clinical trials and their projected commercialization is likely
to boost the market. For instance, Eli Lilly’s Ramucirumab have been approved
by the U.S. Food and Drug Administration (FDA) to be used in combination with
Folfiri for the treatment of metastatic colorectal cancer.
Introduction of technologically
advanced products in this space is mostly focused on detection of methylation
markers associated with cancer development. For example, Epigenomics introduced
Epi proLung BL Reflex Assay which helps in lung cancer diagnosis by determining
methylation of SHOX2 biomarker gene.
For Full Research Report On Epigenetics Drugs & Diagnostic Technologies Market
Visit Here:
https://www.grandviewresearch.com/industry-analysis/epigenetics-drugs-and-diagnostic-technologies-market
Further key
findings from the report suggest:
- Reagents is expected to
account for the largest market share of over USD 7,058.4 million by 2025
owing to increasing R&D in epigenetics. The kits segment is expected
to be in more demand over the forecast period with at CAGR of 20.0% due to
need for rapid and accurate detection techniques
- DNA methylation held the
major market share of the technology segment in terms of revenue over
47.1% in 2017 owing to rising adoption coupled with development of
technological advanced products such as Methylation Sensitive PCR (MSP)
- DNMT inhibitors was the
largest segment in 2017 due to the factors such as wide availability of
these inhibitors and generics in most regions
- Oncology was the largest
revenue generating segment owing to the factors such as growing prevalence
of cancer and strong product pipeline
- North America was observed
to be the major region for epigenetics market accounting for over 39.3%
market share due to high prevalence of cancer, increasing R&D funding,
collaborations among big pharmaceutical companies for development of
improved treatments, and patient awareness
- Asia Pacific is projected to
showcase lucrative CAGR of 22.1% owing to a high number of cancer,
diabetes, and other chronic disorders with parallel unmet medical needs
- Major players operating in
the epigenetics drugs and diagnostic technologies market include Zymo
research; CellCentric Ltd; Thermo Fisher Scientific;Illumina; Abcam; Eisai
Co. Ltd; Diagenode; Merck; Syndax Pharmaceuticals, Inc.; Qiagen; Chroma
Therapeutics Ltd; Novartis International AG; Oncolys Biopharma Inc.;
Sigma-Aldrich Corporation; and Valirx Plc. Widespread R&D activities
and clinical studies are expected to boost the market growth over the
forecast period.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/epigenetics-drugs-and-diagnostic-technologies-market/request/rs1
Grand View Research has segmented
the global epigenetics drugs and diagnostic technologies market on the basis of
product, technology, type of therapy, application, and region:
Epigenetics Drugs
and Diagnostic Technology Product Outlook (Revenue, USD Million, 2014 - 2025)
- Reagents
- Kits
- ChIP Sequencing Kit
- Whole Genomic Amplification
Kit
- Bisulfite Conversion Kit
- RNA Sequencing Kit
- Others
- Instruments
- Enzymes
- Services
Epigenetics Drugs
and Diagnostic Technology Outlook (Revenue, USD Million, 2014 - 2025)
- DNA Methylation
- Histone Methylation
- Histone Acetylation
- Large Non-coding RNA
- MicroRNA Modification
- Chromatin Structures
Epigenetics Drugs
and Diagnostic Technologies Type of Therapy Outlook (Revenue, USD Million, 2014
- 2025)
- Histone Deacetylase (HDAC)
Inhibitors
- DNA Methyltransferase (DNMT)
Inhibitors
Epigenetics Drugs
and Diagnostic Technologies Application Outlook (Revenue, USD Million, 2014 -
2025)
- Oncology
- Solid Tumors
- Liquid Tumors
- Non-oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
Epigenetics Drugs
and Diagnostic Technologies Regional Outlook (Revenue, USD Million, 2014 -
2025)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based
market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment